(function(){ var content_array=["

关于阿斯利康<\/u><\/b><\/p> \n

阿斯利康是一家科学至上的全球性生物制药企业，专注于研发、生产及营销处方类药品，重点关注肿瘤、罕见病、心血管、肾脏及代谢、呼吸和免疫等疾病领域。总部位于英国剑桥的阿斯利康业务遍布100多个国家，创新药物惠及全球数百万患者。更多信息，请访问www.astrazeneca.com<\/a>。<\/p> \n

关于阿斯利康中国<\/u><\/b><\/p> \n

自1993年进入中国以来，阿斯利康坚持科学至上，注重创新，以满足中国不断增长的健康需求，实现"开拓创新，造福病患，成为中国最值得信赖的医疗合作伙伴"这一宏伟愿景。阿斯利康的中国总部位于上海，并分别在北京、广州、无锡、杭州、成都建立区域总部。公司在江苏无锡和泰州投资建有生产基地，并在无锡建立了中国物流中心。在中国，阿斯利康的业务重点主要集中在中国患者需求最迫切的治疗领域，包括呼吸、心血管、代谢、肿瘤、消化、肾脏及罕见病。2017年，中国健康物联网创新中心在无锡落地，旨在探索创新的健康物联网诊疗一体化全病程管理解决方案。同年，阿斯利康与国投创新合资成立迪哲（江苏）医药有限公司，以加快本土新药研发步伐。2019年，阿斯利康宣布与无锡合作共建无锡国际生命科学创新园，汇聚全球智慧，造福中国患者。2020年，阿斯利康宣布支持"互联网医院"项目。2021年，阿斯利康正式升级位于上海的全球研发中国中心，并与中金资本联合发起阿斯利康中金医疗产业基金。<\/p> \n

声明
<\/i>部分研究中的药品用法尚未在中国获批适应症，阿斯利康不推荐任何未被批准的药品使用。<\/i><\/p> \n

参考文献<\/b><\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

1.     Paolo Ghia, Andrzej Pluta, Małgorzata Wach, et al. Acalabrutinib Versus Investigator's Choice in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere 6(12):p e801, December 2022.<\/span><\/p> <\/td> \n <\/tr> \n

2.     Yang, Shenmiao, Huang, Haiwen, Zhou, Keshu, et al. EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED\/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1\/2 TRIAL. HemaSphere. 2023.<\/span><\/p> <\/td> \n <\/tr> \n

3.     https:\/\/www.cancer.gov\/types\/leukemia\/patient\/cll-treatment-pdq#_1.<\/span><\/p> <\/td> \n <\/tr> \n

4.     《慢性淋巴细胞白血病\/小淋巴细胞淋巴瘤诊疗指南（2022年版）》<\/span><\/p> <\/td> \n <\/tr> \n

5.     朱华渊, 等. CLL-IPI评分系统在中国慢性淋巴细胞白血病患者中的预后评估价值[J]. 中华血液学杂志.2018;39(5):392-7<\/span><\/p> <\/td> \n <\/tr> \n

6.     NCCN Guidelines Version 1.2023 Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma<\/span><\/p> <\/td> \n <\/tr> \n

7.     《中国临床肿瘤学会（CSCO）淋巴瘤诊疗指南（2023版）》<\/span><\/p> <\/td> \n <\/tr> \n

8.     Yao Y, Lin X, Li F, Jin J, Wang H. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022 Jan 11;21(1):4. doi: 10.1186\/s12938-021-00973-6. PMID: 35016695; PMCID: PMC8753864.<\/span><\/p> <\/td> \n <\/tr> \n

9.     National Cancer Institute. Cancer stat facts: leukemia — chronic lymphocytic leukemia (CLL). https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed May 2022.<\/span><\/p> <\/td> \n <\/tr> \n

10.  American Cancer Society. What is chronic lymphocytic leukemia. https:\/\/www.cancer.org\/cancer\/chronic-lymphocytic-leukemia\/about\/what-is-cll.html. Accessed May 2022.<\/span><\/p> <\/td> \n <\/tr> \n

11.  National Cancer Institute.  Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version. https:\/\/www.cancer.gov\/types\/leukemia\/patient\/cll-treatment-pdq. Accessed May 2022<\/a>.<\/span><\/p> <\/td> \n <\/tr> \n

12.  Ghia P, Pluta A, Wach M, et al. Acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia (ASCEND): a randomized phase 3 trial. J Clin Oncol. 2020;25: 2849-2861. doi: 10.1200\/JCO.19.03355.<\/span><\/p> <\/td> \n <\/tr> \n

13.  ClinicalTrials.gov. Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies. NCT identifier: NCT03932331.  https:\/\/www.clinicaltrials.gov\/study\/NCT03932331?term=NCT03932331&rank=1. Accessed August 2023.A<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

 <\/p>"]; $("#dvExtra").html(content_array[0]);})();